慢性腎臓病の評価と管理のためのKDIGO診療ガイドライン

出版社: 東京医学社
著者:
発行日: 2014-07-15
分野: 臨床医学:内科  >  腎臓
ISBN: 9784885632358
電子書籍版: 2014-07-15 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

3,740 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,740 円(税込)

商品紹介

すべての慢性腎臓病患者における評価、管理そして治療に関する最新のガイダンスを提供するガイドライン。各条文ごとにGRADE法に準拠したエビデンスの質の評価と推奨事項の強度、理論的根拠、国際的な関連性等を示す。

目次

  • 慢性腎臓病の評価と管理のためのKDIGO診療ガイドライン

    ―目次―

    1章 CKDの定義と分類
    2章 CKD進行の定義、発見法およびその予測
    3章 CKDの進行と合併症の管理
    4章 CKDのその他の合併症:心血管疾患(CVD)、薬剤投与量、
       患者の安全性、感染症、入院、およびCKD合併症診断の
       注意事項
    5章 専門医への紹介と疾患管理モデル

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

References

P.163 掲載の参考文献
1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification. Am J Kidney Dis 2002 ; 39 : S1-266.
7. KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney inter., Suppl. 2012 ; 2 : 1-138.
8. KDIGO GN Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney inter., Suppl. 2012 ; 2 : 139-274.
9. KDIGO CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009 ; 76 (Suppl 113) : S1-130.
10. KDIGO BP Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney inter., Suppl. 2012 ; 2 : 337-114.
11. KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney inter., Suppl. 2012 ; 2 : 279-335.
20. Wesson L. Physiology of the human kidney. Grune & Stratton : New York, 1969.
53. Waters AM. Chapter 6, Part 2 : Functional development of the nephron. In : Geary DF, Schaefer F (eds). Comprehensive Pediatric Nephrology, Mosby Elsevier : Philadelphia, PA, 2008, pp 111-129.
69. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2008 Annual Report, (https://web.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf). Accessed September 7, 2012.
92. Levey AS, Greene T, Kusek J et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000 ; 11 : 155A.
106. Redal-Baigorri B, Stokholm KH, Rasmussen K et al. Estimation of kidney function in cancer patients. Dan Med Bull 2011 ; 58 : A4236.
125. Newman DJ, Thakkar H, Medcalf EA et al. Use of urine albumin measurement as a replacement for total protein. Clin Nephrol 1995 ; 43 : 104-109.
129. Shihabi ZK, Konen JC, O'Connor ML. Albuminuria vs urinary total protein for detecting chronic renal disorders. Clin Chem 1991 ; 37 : 621-624.
130. Martin H. Laboratory measurement of urine albumin and urine total protein in screening for proteinuria in chronic kidney disease. Clin Biochem Rev 2011 ; 32 : 97-102.
133. McElderry LA, Tarbit IF, Cassells-Smith AJ. Six methods for urinary protein compared. Clin Chem 1982 ; 28 : 356-360.
134. Nishi HH, Elin RJ. Three turbidimetric methods for determining total protein compared. Clin Chem 1985 ; 31 : 1377-1380.
141. Marshall T, Williams KM. Total protein determination in urine : elimination of a differential response between the coomassie blue and pyrogallol red protein dye-binding assays. Clin Chem 2000 ; 46 : 392-398.
144. Medicines and Healthcare products Regulatory Agency. MHRA 04086 Point of care devices for the quantitation of microalbuminuria. 2004.
145. Medicines and Healthcare products Regulatory Agency. MHRA 04098. Point of care devices for the detection and semi-quantitation of microalbuminuria. 2004.
146. Parsons M, Newman DJ, Pugia M et al. Performance of a reagent strip device for quantitation of the urine albumin : creatinine ratio in a point of care setting. Clin Nephrol 1999 ; 51 : 220-227.
147. Parsons MP, Newman DJ, Newall RG et al. Validation of a point-of-care assay for the urinary albumin:creatinine ratio. Clin Chem 1999 ; 45:414-117.
156. Gyure WL. Comparison of several methods for semiquantitative determination of urinary protein. Clin Chem 1977 ; 23 : 876-879.
168. Hutchison AS, O'Reilly DS, MacCuish AC. Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clin Chem 1988 ; 34 : 2019-2021.
171 Chitalia VC, Kothan J, Wells EJ et al. Cost-benefit analysis and prediction of 24-hour proteinuria trom the spot urine protein-creatinine ratio. Clin Nephrol 2001 ; 55 : 436-47.
173. Dyson EH, Will EJ, Davison AM et al. Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. Nephrol Dial Transplant 1992 ; 7 : 450-52.
176. Lemann J, Jr., Doumas BT. Proteinuria in health and disease assessed by measuring the urinary protein/creatinine ratio. Clin Chem 1987 ; 33 : 297-299.
180. Howey JE, Browning MC, Fraser CG. Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation : novel uses of data on biological variation. Clin Chem 1987 ; 33 : 2034-2038.
183. Leung AK, Wong AH. Proteinuria in children. Am Fam Physician 2010 ; 82 : 645-651.
186. National Institute for Health and Clinical Excellence. NICE clinical guideline 73. Chronic kidney disease : early identification and management of chronic kidney disease in adults in primary and secondary care. 2008.
188. Johnson DW, Jones GR, Mathew TH et al. Chronic kidney disease and measurement of albuminuria or proteinuria : a position statement. Med J Aust 2012 ; 197 : 224-225.
189. Scottish Intercollegiate Guidelines Network. Guideline 103. Diagnosis and management of chronic kidney disease. 2008.
190. Caring for Australasians with Renal Impairment, http://www.cari.org.au/guidelines.php
191. Clarke W, Frost SJ, Kraus E et al. Renal function testing. In : Nichols JH (ed) Evidence-based Practice for Point-of-Care Testing. National Academy of Clinical Biochemistry, 2006, pp 126-134.
207. Wrong OM, Norden AG, Feest TG. Dent's disease ; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM 1994 ; 87 : 473-493.
209. Gosling P. Proteinuria. In : Marshall WJ, Bangert SK (eds). Clinical Biochemistry : Metabolic and Clinical Aspects, 2nd Ed. Elsevier, 2008, pp 156-173.
210. Goren MP, Li JT. The Coomassie Brilliant Blue method underestimates drug-induced tubular proteinuria. Clin Chem 1986 ; 32 : 386-388.
211. Weber MH, Verwiebe R. Alpha 1-microglobulin (protein HC) : features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem 1992 ; 30 : 683-691.
212. Herget-Rosenthal S, Poppen D, Husing J et at. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004 ; 50 : 552-558.
216. Slack TK, Wilson DM. Normal renal function : CIN and CPAH in healthy donors before and after nephrectomy. Mayo Clinic Proc 1976 ; 51 : 296-300.
226. Levey AS, Gassman JJ, Hall PM et al. Assessing the progression of renal disease in clinical studies : effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol 1991 ; 1 : 1087-1094.
228. Wright JT, Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial. JAMA 2002 ; 288 : 2421-2431.
248. O'Hare AM, Batten A, Burrows NR et al. Trajectories of Kidney Function Decline in the 2 Years Before Initiation of Long-term Dialysis. Am J Kidney Dis 2012 ; 59 : 513-522.
250. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008 ; 78 : 743-750.
266. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention : incidence, risk factors, and relationship to mortality. Am J Med 1997 ; 103 : 368-375.
289. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2009 : CD002181.
298. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 ; 352 : 837-853.
299. Ichikawa H, Nagake Y, Takahashi M et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? Nihon Jinzo Gakkai Shi 1996 ; 38 : 305-308.
305. American Diabetes Association. Executive summary : Standards of medical care in diabetes-2012. Diabetes Care 2012 ; 35 (Suppl 1) : S4-S10.
306. Jones-Burton C, Mishra SI, Fink JC et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006 ; 26 : 268-275.
326. Padilla J, Krasnoff J, Da Silva M et al. Physical functioning in patients with chronic kidney disease. J Nephrol 2008 ; 21 : 550-559.
328. Churchill DN, Torrance GW, Taylor DW et al. Measurement of quality of life in end-stage renal disease : the time trade-off approach. Clin Invest Med 1987 ; 10 : 14-20.
333. Daul AE, Schafers RF, Daul K et al. Exercise during hemodialysis. Clin Nephrol 2004 ; 61 (Suppl 1) : S26 30.
334. Deligiannis A. Cardiac adaptations following exercise training in hemodialysis patients. Clin Nephrol 2004 ; 61 (Suppl 1) ; S39-45.
335. Liu SH, C. LC, Yeh SH et al. Effect of exercise training on hemodialysis. Journal of the Formosan Medical Association 2002 ; 6 : 129-142.
341. Szromba C, Thies MA, Ossman SS. Advancing chronic kidney disease care : new imperatives for recognition and intervention. Nephrol Nurs J 2002 ; 29 : 547-559.
362. Gambaro G, Bax G, Fusaro M et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 2001 ; 14 : 337-342.
373. Centers for Disease Control and Prevention. CDC criteria for anemia in children and childbearing-aged women. MMWR Morb Mortal Wkly Rep 1989 ; 38 : 400-104.
411. Bright R. Reports of Medical Cases, Selected with a View of Illustrating the Symptoms and Cure of Diseases by a Reference to Morbid Anatomy, Volume 1. London : Brown & Green. 1827.
419. Husted FC, Nolph KD. NaHC03 and NaCI tolerance in chronic renal failure II. Clin Nephrol 1977 ; 7 : 21-25.
425. Samak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003 ; 41 : 11-17.
453. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice : executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 ; 14 (Suppl 2) : EI-M).
465. Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. J Pediatr Pharmacol Ther 2010 ; 15 : 160-172.
474. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the 499. renal patient. J Am Soc Nephrol 2001 ; 12 : 1079-1084.
479. Ahmed A, Rich MW, Sanders PW et ak, Cgribuc judbet dusease assicuated mortality in diastolic versus systolic heart failure : a propensity matched study. Am J Cardiol 2007 ; 99 : 393-398.
495. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides : a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003 ; 4 : 72-80.
501. Vickery S, Price CP, John RI et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD : relationship to renal function and left ventriculary hypertrophy. Am J Kidney Dis 2005 ; 46 : 610-620.
503. Takahashi M, Nagake Y, Ichikawa H et al. Plasma concentrations of natriuretic peptides in patients on hemodialysis. Res Commun Mol Pathol Pharmacol 1996 ; 92 : 19-30.
509. Bettencourt P, Azevedo A, Pimenta J et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004 ; 110 : 2168 2174.
511. Kragelund CB, Gronning BA, Kober L et al. [Prognostic value of N-terminal pro-BNP-type natriuretic peptide in patients with stable coronary heart disease-secondary publication], Ugeskr Laeger 2006 ; 168 : 697-700.
516. Barret BJ, Culleton B. Reducing the burden of cardiovascular disease in patients on dialysis. Dial Transplant 2002 ; 31 : 155-163.
519. McLaurin MD, Apple FS, Voss EM et al. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease : evidence of cardiac troponin T expression in skeletal muscle. Clin Chem 1997 ; 43 : 976-982.
543. Needham DM, Shufelt KA, Tomlinson G et al. Troponin I and T levels in renal failure patients without acute coronary syndrome : a systematic review of the literature. Can J Cardiol 2004 ; 20 : 1212-1218.
552. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999 ; 10 : 1606-1615.
559. Braun WE, Phillips DF, Vidt DG et al. Coronary artery disease in 100 diabetics with end-stage renal failure. Transplant Proc 1984 ; 16 : 603-607.
560. Lorber Ml, Van Buren CT, Flechner SM et al. Pretransplant coronary arteriography for diabetic renal transplant recipients. Transplant Proc 1987 ; 19 : 1539-1541.
563. Klocke FJ, Baird MG, Lorell BH et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003 ; 42 : 1318-1333.
590. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) : developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 ; 114 : e257-354.
592. O'Hare AM, Bertenthal D, Sidawy AN et al. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol 2006 ; 1 : 297-304.
593. Goodman and Gilman's Pharmacological Basis of Therapeutics, 12th Edn. Brunston LL, Chabner BA, Knollman BA (eds). McGraw-Hill : New York, 2011.
594. Martindale : The Complete Drug Reference, 37th Edn. Sweetman SC (ed). Royal Pharmaceutical Society, London, 2011.
597. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 38 : Bipolar Disorder. 2006.
600. Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010 : CD002967.
608. Drug prescribing in renal failure, http://www.kdp-baptist.louisville.edu/renalbook/.
610. American College Radiology Guidelines. Manual on Contrast Media Version 8. http://www.acr.0rg/~/media/ACR/D0cuments/PDF/QualitySafety/Resources/Contrast%20Manual/Contrast%20Nephrotoxicity.pdf. Accessed October 12, 2012.
611. European Society for Urological Radiology (ESUR). http://www.esur.org/Contrast-media.51.0.html, Accessed October 9, 2012.
614. Agarwal R, Brunelli SM, Williams K et at. Gadolinium-based contrast agents and nephrogenic systemic fibrosis : a systematic review and metaanalysis. Nephrol Dial Transplant 2009 ; 24 : 856-863.
615. American College Radiology Guidelines. Manual on Contrast Media Version 8. http://www.acr.org/~/media/ACR/Documents/PDF/Quality-Safety/Resources/Contrast%20Manual/Nephrogenic%20Systemic%20Fibrosis.pdf. Accessed October 12, 2012.
631. US Renal Data System. Atlas of Chronic Kidney Disease in the United States. Bethesda, MD : National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. 2007.
633. US Renal Data System. Atlas of Chronic Kidney Disease in the United States. Bethesda, MD : National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. 2010.
634. Mclntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health 1998 ; 34 : 314-317.
635. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease : a review. J Am Soc Nephrol 1993 ; 3 : 1541-1554.
636. Cohen G, Haag-Weber M, Horl WH. Immune dysfunction in uremia. Kidney Int Suppl 1997 ; 62 : S79-82.
645. Dinits-Pensy M, Forrest GN, Cross AS et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005 ; 46 : 997-1011.
650. CDC immunization schedules, http://www.cdc.gov/vaccines/schedules/index.html.
651. American Academy of Pediatrics. Immunization : http://www2.aap.org/immunization/.
659. Arora P, Kausz AT, Obrador GT et al. Hospital utilization among chronic dialysis patients. J Am Soc Nephrol 2000 ; 11 : 740-746.
662. Popovic JR, Kozak LJ. National hospital discharge survey : annual summary, 1998. Vital Health Stat 13 2000 : 1-194.
663. Rocco MV, Soucie JM, Reboussin DM et al. Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). J Am Soc Nephrol 1996 ; 7 : 889-896.
670. De Coster C, McLaughlin K, Noseworthy TW. Criteria for referring patients with renal disease for nephrology consultation : a review of the literature. J Nephrol 2010 ; 23 : 399-07.
678. Barakat AJ, Chesney RW (eds.). Pediatric Nephrology for Primary Care. American Academy of Pediatrics : Illinois, 2009.
681. Epping-Jordan JE, Pruitt SD, Bengoa R et al. Improving the quality of health care for chronic conditions. Qua! Saf Health Care 2004 ; 13 : 299-305.
685. Traynor JP, Simpson K, Geddes CC et al. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002 ; 13 : 2125-2132.
692. Shiao CC, Huang JW, Chien KL et al. Early initiation of dialysis and late implantation of catheters adversely affect outcomes of patients on chronic peritoneal dialysis. Perit Dial Int 2008 ; 28 : 73-81.
705. Murphy EL, Murtagh FE, Carey I et at. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis : use of a short patient-completed assessment tool. Nephron Clin Pract 2009 ; 111 : C74-80.
709. Temel JS, Greer JA, Muzikansky A et al. Larly palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010 ; 363 : 733-742.
712. Davison SN, Murtagh FE, Higginson IJ. Methodological considerations for end-of-life research in patients with chronic kidney disease. J Nephrol 2008 ; 21 : 268-282.
718. Higginson IJ, Wade AM, McCarthy M. Effectiveness of two palliative support teams. J Public Health Med 1992 ; 14 : 50-56.
721. Fassbender K, Smythe JG, Carson M, et al. Report of the Institute for Public Economics Health Research Group to Alberta Health and Wellness : cost and utilization of health care services at end of life in Alberta, 1999-2002. Edmonton, AB : University of Alberta. 2006.
726. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines : the AGREE project. Qua! Saf Health Care 2003 ; 12 : 18-23.
728. Institute of Medicine. Finding What Works in Health Care : Standards for Systematic Reviews. The National Academies Press : Washington, DC, 2011.
729. Institute of Medicine. Clinical Practice Guidelines We Can Trust. The National Academies Press : Washington, DC, 2011.

最近チェックした商品履歴

Loading...